Metraipolis › archive › dc_4de36f41508d
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis — Europe PMC PMID:42637879
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42637879
- DOI
- 10.1038/s41375-[numero omesso]-9
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-31T10:35:46.518Z
- SHA-256 of the archived text
217c252f37cff4802c3bc1ca1cbba5cf16ca96de5923bb950d6032081074b0ac- Stable URL of this page
https://metraipolis.com/documento/dc_4de36f41508d
How to cite
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis — Europe PMC PMID:42637879 — Europe PMC (en), https://europepmc.org/article/MED/42637879 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4de36f41508d (Metraipolis archive dc_4de36f41508d, sha256 217c252f37cff4802c3bc1ca1cbba5cf16ca96de5923bb950d6032081074b0ac)
BibTeX
@misc{dc4de36f41508d,
title = {Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis — Europe PMC PMID:42637879},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42637879},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4de36f41508d; sha256 217c252f37cff4802c3bc1ca1cbba5cf16ca96de5923bb950d6032081074b0ac},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42637879. Agents can read the archived copy with the MCP tool read_document.